Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05916378 · ClinicalTrials.gov registry record

Achieving Equity in Genomic Testing for Breast Cancer Through Partner-Led Strategies and Policies

A clinical trial of Breast Cancer, sponsored by Stanford University.

Active
Registry status
150
Enrollment target
1
Study location

NCT05916378: Active study of Breast Cancer, sponsored by Stanford University.

NCT05916378 is a study of Breast Cancer that is active but no longer recruiting, run by Stanford University. The registered enrollment target is 150 participants, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (95% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05916378, a study of Breast Cancer, is active but no longer recruiting, sponsored by Stanford University.

ACTIVE NOT RECRUITING
Registry status
150 participants
Enrollment target
1
Study location

Study Summary

The purpose of this study is to identify the barriers, and the extent of said barriers, to genomic testing for breast cancer patients among low-income and minority populations, particularly throughout Northern California. The investigators have created a survey that is available online for any patient with cancer to fill out voluntarily regarding their experiences to date. The survey is available at: https://stanforduniversity.qualtrics.com/jfe/form/SV\_7VElf8oesWcB3bE

Conditions Studied

Study Locations (1)

California

  • Stanford University School of Medicine - Stanford

Trial Details

FieldValue
Enrollment Target 150 participants
Start Date 2023-05-22
Est. Completion 2025-03-30

Sponsor

Stanford University

1,744 total trials

What the Registry Record Tells You About NCT05916378

The ClinicalTrials.gov registry entry for NCT05916378 describes a study currently listed as active not recruiting, categorized as an unspecified phase. The registered enrollment target is 150 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (95% lower). The listed sponsor is Stanford University, which has 1,744 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Breast Cancer appearing as the primary indexed condition, and to 0 interventions.

NCT05916378 reports 1 study location spanning 1 distinct geographic area - top geographies include California.

Frequently Asked Questions

What is clinical trial NCT05916378 about?

NCT05916378 is a clinical study titled "Achieving Equity in Genomic Testing for Breast Cancer Through Partner-Led Strategies and Policies". The purpose of this study is to identify the barriers, and the extent of said barriers, to genomic testing for breast cancer patients among low-income and minority populations, particularly throughout Northern California. The investigators have created a survey that is available online for any patie...

What is the current status of trial NCT05916378?

This trial is currently active not recruiting. The enrollment target is 150 participants. The study started on 2023-05-22. Estimated completion is 2025-03-30.

What conditions does trial NCT05916378 study?

This clinical trial studies the following conditions: Breast Cancer.

Who is sponsoring clinical trial NCT05916378?

This trial is sponsored by Stanford University, which has 1,744 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05916378 being conducted?

This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Breast Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.